CASI Pharma Raises $25 Million in Secondary Offering

CASI Pharma, a US-China biopharma, raised $25 million in a secondary offering, which it will use to fund clinical trials. CASI currently has four Phase II trials of ENMD-2076, an oral Aurora A/angiogenic kinase inhibitor, underway in the US and China in patients with various kinds of cancer. Headquartered in Maryland, CASI has R&D operations in Beijing. The financing was led by a China investment fund manager affiliated with the same management team as CASI's largest shareholder, IDG-Accel China Growth Fund III, L.P. More details.... Stock Symbol: (NSDQ: CASI) Share this with colleagues: // //